Applied Tissue Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Applied Tissue Technologies is an innovation-driven wound care company focused on regenerative medicine and medical devices. Its flagship Platform Wound Device (PWD) represents a potential paradigm shift in negative pressure wound therapy by eliminating the need for a wound contact layer, enabling direct topical drug delivery, and simplifying deployment in austere environments. With strong foundational support from U.S. Department of Defense grants and a seasoned leadership team anchored by a renowned plastic surgeon, ATT is advancing its PWD through clinical studies while addressing both military and large-scale civilian wound care needs.

Wound HealingBurnsTraumatic Injuries

Technology Platform

Platform Wound Device (PWD): A sealed polyurethane wound chamber with embossed micro-structures for Negative Pressure Wound Therapy (NPWT) without foam/gauze, enabling concurrent topical delivery of therapeutics (analgesics, antimicrobials).

Opportunities

The PWD addresses a significant gap in military and disaster medicine for simplified, deployable wound care, supported by strong DoD partnerships.

In the broader civilian market, its foam-free design and integrated drug delivery offer potential advantages over established NPWT systems in reducing patient trauma and improving outcomes.

Risk Factors

Clinical development risks remain, as the PWD must prove safety and efficacy in ongoing trials.

As a small private company, ATT faces formidable commercialization challenges against large, entrenched competitors in the NPWT market and may face funding constraints beyond its current grant support.

Competitive Landscape

ATT competes in the large and competitive advanced wound care market, directly challenging established NPWT leaders like 3M (KCI), Smith & Nephew, and Cardinal Health. Its differentiation lies in eliminating the wound contact layer and enabling topical delivery, but it must overcome high barriers to adoption and significant sales/marketing resources possessed by incumbents.

More companies in Regenerative Medicine →More companies in United States →